Clinical Trial News and Research

RSS

Early detection methods can help cure cervical cancer

Cervical cancer, a disease that will affect more than 12,000 women in the United States this year and more than a half million women worldwide, leads to significantly fewer deaths when effective early detection methods are available, either via a Pap smear or with a test for presence of the human papilloma virus.

4 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

GRACE study reports colored women are poorly represented in HIV drug trials

Enrollment of women in clinical trials of new anti-HIV drugs is extremely low, representing only about 15% of all treatment-experienced patients. For women of color it is even lower.

3 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn't work, or can't be used again, a second, effective option now exists.

3 Jun 2013

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.

1 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

NYC public health officials launch new program to locate lost to follow-up patients with HIV

Public health officials in New York City have launched a successful program to locate HIV-positive patients who have been "lost to follow-up" and reconnect them with treatment services, reports a study published in AIDS, official journal of the International AIDS Society.

31 May 2013

Clinical Trial News and Research

Early detection methods can help cure cervical cancer

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

GRACE study reports colored women are poorly represented in HIV drug trials

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

MRIgFU ablation therapy reduces pain in 67% of patients with bone tumors

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

New therapy for lung cancer produces manageable side effects

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

GLYX-13 drug induces antidepressant results without street drug side effects

Omeros announces positive results from OMS824 Phase 1 clinical program

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

NYC public health officials launch new program to locate lost to follow-up patients with HIV

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer